Vida, Bayer throw weight behind $175M T-cell startup

yellow cells

Affini-T Therapeutics has formally launched with $175 million in venture capital, one clinical-stage drug licensed from Fred Hutch and two more solid tumor-targeting drugs that should enter the clinic next year.

New Cell Therapy Player Makes Public Debut at JPM

Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients. First reported by Geek Wire, Affini-T, based in Boston, is harnessing T cell […]

Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer

A new cell therapy company is on the block, propelled by powerhouse scientific co-founders from Fred Hutchinson Cancer Research Center with years of experience investigating how to harness the immune system to treat cancer. Affini-T Therapeutics, which emerged Wednesday in a presentation at the J.P. Morgan Health Care Conference, is headquartered in Boston and has […]

A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies

There are two things Phil Greenberg, the head of immunology at Fred Hutchinson Cancer Research Center, is especially well-known for: a characteristic wiry gray mop of hair and wide glasses, and a rock-solid reputation as one of the leading researchers in cancer immunotherapy. Greenberg was behind some of the key scientific advances that led to […]